Gilead faces fresh Sovaldi challenge

Gilead Sciences is facing a challenge to its attempt to obtain a patent for its hepatitis C drug Sovaldi (sofosbuvir) in certain Asian, Latin American and European countries.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Public interest group challenges ‘unmerited’ Gilead patents

26 October 2017 Non-profit group the Initiative for Medicines, Access & Knowledge (I-MAK) has accused Gilead of obtaining “unmerited patents” for its hepatitis C medicine sofosbuvir.

Asia

Indian Pharmaceutical Alliance drops Sovaldi opposition

16 September 2015 The Indian Pharmaceutical Alliance has dropped its opposition to a patent application filed by Gilead Sciences covering its hepatitis C drug Sovaldi.

Asia-Pacific

SIPO rejects Gilead’s Sovaldi patent application

23 June 2015 China’s State Intellectual Property Office has rejected Gilead Sciences’s patent application covering its Sovaldi (sofosbuvir) drug after it was challenged by a non-profit group.

More features

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

Killing the golden goose of US drug innovation (Part I): Follow the money

Buchalter brings in new partner to head up medtech

Trump’s march-in rights threat: Why pharma is rethinking collaborations

Gilead faces fresh Sovaldi challenge

More on this story

Editor's picks

Editor's picks

More features